ATE241982T1 - Verfahren zur hemmung von diabetischen komplikationen - Google Patents

Verfahren zur hemmung von diabetischen komplikationen

Info

Publication number
ATE241982T1
ATE241982T1 AT99955093T AT99955093T ATE241982T1 AT E241982 T1 ATE241982 T1 AT E241982T1 AT 99955093 T AT99955093 T AT 99955093T AT 99955093 T AT99955093 T AT 99955093T AT E241982 T1 ATE241982 T1 AT E241982T1
Authority
AT
Austria
Prior art keywords
diabetic complications
instant invention
post
age formation
methods
Prior art date
Application number
AT99955093T
Other languages
English (en)
Inventor
John W Baynes
Suzanne R Thorpe
Thorsten P Degenhardt
Raja Gabriel Khalifah
Billy Hudson
Nathan Alderson
Original Assignee
Univ South Carolina
Kansas University Medical Ct R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina, Kansas University Medical Ct R filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE241982T1 publication Critical patent/ATE241982T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
AT99955093T 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen ATE241982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10518298P 1998-10-22 1998-10-22
PCT/US1999/024611 WO2000023063A2 (en) 1998-10-22 1999-10-21 Methods for inhibiting diabetic complications

Publications (1)

Publication Number Publication Date
ATE241982T1 true ATE241982T1 (de) 2003-06-15

Family

ID=22304498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955093T ATE241982T1 (de) 1998-10-22 1999-10-21 Verfahren zur hemmung von diabetischen komplikationen

Country Status (8)

Country Link
EP (1) EP1121121B1 (de)
JP (1) JP3864050B2 (de)
AT (1) ATE241982T1 (de)
AU (2) AU762030B2 (de)
CA (1) CA2347117C (de)
DE (1) DE69908630T2 (de)
ES (1) ES2197689T3 (de)
WO (1) WO2000023063A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341532B1 (de) * 2000-11-02 2006-07-26 University of South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
CA2529538C (en) * 2003-06-20 2011-04-26 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
AU2004287434B2 (en) * 2003-10-27 2011-04-07 City Of Hope Methods of lowering lipid levels in a mammal
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
US20090030047A1 (en) * 2005-05-24 2009-01-29 Tokai University Educational System Peritoneum protecting agent
WO2008013660A2 (en) * 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
JP5128003B2 (ja) * 2010-07-23 2013-01-23 学校法人東海大学 腹膜透析患者用の経口医薬組成物及びその用法
JP6148127B2 (ja) * 2013-09-09 2017-06-14 株式会社パーマケム・アジア ピリドキサール・アミノグアニジン誘導体またはそれらの塩、及び、その製造方法
CN107148272A (zh) * 2014-08-29 2017-09-08 吡哆胺研究有限公司 通过组合吡哆胺化合物和硫胺化合物形成的药物组合物
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
EP3510014A4 (de) * 2016-09-06 2020-05-20 Metabolic Technologies, Inc. Zusammensetzungen und verfahren zur verwendung von gamma-ketoaldehyd-fängern zur behandlung, prävention oder verbesserung von nichtalkoholischer fettlebererkrankung (nafld), nash, ald oder erkrankungen im zusammenhang mit der leber
JP2022542518A (ja) 2019-08-01 2022-10-04 プラエテゴ インコーポレイテッド 終末糖化産物の抑制剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH607773A5 (en) * 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
FR2349330A1 (fr) * 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
CA2049940C (en) * 1990-02-19 1996-03-05 Jun Inoue Maillard's reaction inhibitor compositions
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
JPH10158244A (ja) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd ５−アミノアルキル−４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
JPH10175954A (ja) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd ４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤

Also Published As

Publication number Publication date
AU762030B2 (en) 2003-06-19
EP1121121B1 (de) 2003-06-04
WO2000023063A2 (en) 2000-04-27
EP1121121A2 (de) 2001-08-08
AU2003248205A1 (en) 2003-10-30
DE69908630D1 (de) 2003-07-10
JP3864050B2 (ja) 2006-12-27
AU1127400A (en) 2000-05-08
WO2000023063A3 (en) 2000-07-13
CA2347117C (en) 2006-01-24
JP2002527471A (ja) 2002-08-27
ES2197689T3 (es) 2004-01-01
CA2347117A1 (en) 2000-04-27
DE69908630T2 (de) 2004-04-29

Similar Documents

Publication Publication Date Title
DE69908630D1 (de) Verfahren zur hemmung von diabetischen komplikationen
EA200100702A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
ATE409037T1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69726815D1 (de) Verfahren zur Frakturierung von unterirdischen Lagerstätten
DE60101669T2 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE69701714T2 (de) Verfahren zur behandlung von glassubstraten
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
DE69603089T2 (de) Zusammensetzung zur behandlung von mauerwerk
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
NO20011351D0 (no) FremgangsmÕte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
ATE426061T1 (de) Verfahren zur behandlung von textilen fasermaterialien
DE69631891D1 (de) Verfahren zur hemmung der bildung von hydraten
DE69904156D1 (de) Verfahren zur inhibierung der ablagerung von weisspech in der papierherstellung
DE60131545D1 (de) Verfahren zur behandlung von reaktiver arthritis oder schleimbeutelentzündung
ATE232919T1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
WO2000021516A3 (en) Methods for inhibiting diabetic complications
DE69817080D1 (de) Verfahren zur Verminderung des Sauregehalts von Rohöl
ATE291909T1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
DE60119671D1 (de) Verfahren zur Behandlung von Holzwerkstoff
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
DE60221734D1 (de) Verfahren zur Verhinderung von Ablagerungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties